FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus

Article Link: FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus

2 August 2021 — AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.1
The approval by the…

Source: FDA New Drug Approvals